Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury
Launched by METROHEALTH MEDICAL CENTER · Nov 15, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new treatment option for people with spinal cord injuries (SCI) who experience fecal incontinence, which is the inability to control bowel movements. The study will test a technique called genital nerve stimulation (GNS) using non-invasive electrodes to see if it can help improve bowel function and reduce accidents. By measuring how the anus and rectum respond to this stimulation, researchers hope to understand if GNS can make a positive difference for those living with SCI.
To participate in the study, individuals must be at least 18 years old and have experienced a traumatic spinal cord injury for at least six months. They should also have a neurological injury at T12 level or higher and show a response to the genital nerve stimulation during screening. Participants will be asked to undergo several tests to monitor bowel function, and the study will collect information about their health and daily life. This research aims to provide more options for managing bowel issues, which can significantly affect quality of life for people with spinal cord injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Traumatic SCI
- • Minimum 6 months post-injury
- • Aged 18 years or older
- • Neurological level of injury T12 or higher AIS grade A-D defined by ISNCSCI
- • Response to genital nerve stimulation upon screening
- • Able to understand and provide informed consent
- Exclusion Criteria:
- • Currently enrolled in another functional electrical stimulation (FES) research trial
- • Females who are pregnant or planning to become pregnant during the trial
- • Presence of cardiac pacemaker, implanted defibrillator or other implanted FES device if, upon clinical exam, it may have an interaction with GNS.
- • In the judgement of the PI or Co-Investigators, presence of medical complications that may interfere with the execution of the study.
About Metrohealth Medical Center
MetroHealth Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor, MetroHealth collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. With a commitment to ethical research practices and participant safety, the center leverages its extensive resources and expertise to contribute to the scientific community and enhance healthcare outcomes. Through rigorous clinical trials, MetroHealth aims to translate research findings into tangible benefits for patients, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
Kim Anderson, PhD
Principal Investigator
MetroHealth Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials